Yulan Sun
Overview
Explore the profile of Yulan Sun including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
674
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang D, Qi X, Li F, Chu Y, Wu K, Li J, et al.
Biosaf Health
. 2025 Mar;
5(4):187-190.
PMID: 40078229
Monkeypox (mpox) is a zoonotic disease caused by the mpox virus (MPXV) that has been primarily limited to Central and West African nations since its discovery. The recent spread of...
2.
Xiong A, Wang L, Chen J, Wu L, Liu B, Yao J, et al.
Lancet
. 2025 Mar;
405(10481):839-849.
PMID: 40057343
Background: Ivonescimab is a bispecific antibody against programmed cell death protein 1 and vascular endothelial growth factor, yielding promising clinical outcomes for patients with advanced non-small cell lung cancer in...
3.
Zhang B, Cao Y, Qu Z, Sun Y, Tian X
Endocrine
. 2024 Aug;
87(1):136-143.
PMID: 39190051
Background: Metformin, a widely used antihyperglycemic drug, has shown efficacy in treating type 2 diabetes mellitus (T2DM) and is associated with potential benefits beyond glycemic control. This study investigates the...
4.
Niu J, Jing X, Xu Q, Liu H, Tian Y, Yang Z, et al.
Future Oncol
. 2024 Aug;
20(32):2481-2490.
PMID: 39155845
In first/second generation EGFR-TKIs, strong PD-L1 expression contributes to primary resistance, significantly affecting patient prognosis. The relationship between PD-L1 expression levels and third-generation TKIs remains unclear. This study analyzed advanced...
5.
Tian X, Qu Z, Sun Y, Zhang B
Heliyon
. 2024 Jul;
10(13):e33673.
PMID: 39071694
Background: Rheumatoid arthritis (RA) is associated with significant mortality, which is primarily due to cardiovascular complications. Despite advancements in RA treatment, mortality rates remain high, highlighting the need for reliable...
6.
Liang Z, Lin C, Huo D, Yang Y, Feng Z, Cui S, et al.
J Med Virol
. 2024 Jul;
96(7):e29796.
PMID: 38982764
Coxsackievirus A16 (CV-A16) is a significant etiologic agent of hand, foot, and mouth disease (HFMD) and herpangina (HA), with the capacity to progress to severe complications, including encephalitis, aseptic meningitis,...
7.
Liu X, Sun Y, Lv X, Song M, Sun J, Sun Y
Int Immunopharmacol
. 2024 Jun;
138:112518.
PMID: 38917528
Lung carcinoma is a frequently encountered cancerous growth that affects the respiratory tract and has a high occurrence rate globally. In light of the ongoing worldwide health emergency, the significance...
8.
Fang W, Zhao Y, Luo Y, Yang R, Huang Y, He Z, et al.
JAMA
. 2024 May;
332(7):561-570.
PMID: 38820549
Importance: For patients with non-small cell lung cancer whose disease progressed while receiving EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy, particularly third-generation TKIs, optimal treatment options remain limited. Objective: To compare...
9.
Wang M, Jing X, Chen F, Lu S, Sun Y
BMC Cancer
. 2024 May;
24(1):569.
PMID: 38714983
Background: No definite conclusion has yet to be reached for immunotherapy beyond progression(IBP) of first-line immunotherapy as the second-line treatment for advanced NSCLC patients with negative driver genes. Therefore a...
10.
Lu S, Guo X, Yang Z, Sun Y, Niu J, Jing X, et al.
Future Oncol
. 2024 Apr;
:1-14.
PMID: 38591950
This study assesses immune checkpoint inhibitors' efficacy for non-small-cell lung cancer (NSCLC) with brain metastases (BM) and explores the role of cranial radiation therapy (CRT) in the immunotherapy era. The...